Clinical Trial

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of SHR-A1811 combined with chemotherapy and immune checkpoint inhibitor versus standard first-line therapy in gastric or gastroesophageal junction adenocarcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-11; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2025-09-03
Trial Details
NCT Number NCT07118527
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 600 participants
Start Date 2025-08-18
Primary Completion 2030-10 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-11